PDX model details
| PDX ID |
27.2A Cx |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Castrate |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
23 (4*) |
| Average PDX Generation Time (days +/- SEM) |
81 ± 9 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304; 30049486 |
| |
|
| Markers |
27.2A Cx |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 27.2A Cx |
MET |
0.853 |
3.614 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
EZH2 |
0.804 |
3.492 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
KMT2C |
0.804 |
3.492 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
CHD7 |
0.765 |
3.398 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
BRAF |
0.759 |
3.385 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
CHD7 |
0.648 |
3.133 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
SETDB1 |
0.586 |
3.003 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
XPO1 |
-0.756 |
1.184 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
ZNRF3 |
-0.880 |
1.087 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
PAX6 |
-0.881 |
1.086 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
SPEN |
-0.893 |
1.077 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
MSH2 |
-0.943 |
1.040 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
ZFHX3 |
-0.962 |
1.027 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
SPEN |
-1.163 |
0.893 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
FANCA |
-1.178 |
0.884 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
MGA |
-1.245 |
0.844 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
FANCA |
-1.393 |
0.762 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
CDH1 |
-1.400 |
0.758 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
AR |
-1.228 |
0.426 |
GSR |
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
CHD1 |
-23.248 |
2.010e-07 |
Homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 27.2A Cx |
RB1 |
-26.409 |
2.240e-08 |
Homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
27.2A |
| Sample Site |
Inguinal lymph node |
| Sample source |
Autopsy |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel, abiraterone |
| |
|
Patient Information
| Patient Number |
27 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
42 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download Plot
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Total Read Depth
|
Alternate Frequency
|
Consequence
|
Exon
|
GnomAD AF
|
CADD PHRED score
|
ClinVar significance
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 27.2A Cx |
PCDH11X |
100 |
0.98 |
Missense variant |
'2/7 |
. |
22.9 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 27.2A Cx |
TH |
171 |
0.6 |
Start lost |
'1/14 |
. |
21.5 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 27.2A Cx |
TH |
171 |
0.6 |
Start lost |
'1/14 |
. |
21.5 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 27.2A Cx |
SON |
203 |
0.55 |
Missense variant |
'3/12 |
. |
25.4 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 27.2A Cx |
LHFPL3 |
271 |
0.54 |
Missense variant |
'1/5 |
. |
26.7 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 27.2A Cx |
CEP128 |
211 |
0.47 |
Missense variant |
'14/25 |
. |
24.4 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 27.2A Cx |
IGF2R |
266 |
0.42 |
Missense variant |
'16/48 |
3.28E-05 |
24 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 27.2A Cx |
AR |
— |
— |
GSR |
— |
— |
— |
— |
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Drug dosing Table